MIND MEDICINE INC
NASDAQ: MNMD (Mind Medicine (MindMed) Inc.)
Last update: yesterday, 4:26AM13.64
0.25 (1.87%)
| Previous Close | 13.39 |
| Open | 13.50 |
| Volume | 1,454,573 |
| Avg. Volume (3M) | 1,940,485 |
| Market Cap | 1,326,069,760 |
| Price / Book | 9.77 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -0.750 |
| Total Debt/Equity (MRQ) | 9.89% |
| Current Ratio (MRQ) | 7.27 |
| Operating Cash Flow (TTM) | -91.95 M |
| Levered Free Cash Flow (TTM) | -96.27 M |
| Return on Assets (TTM) | -25.84% |
| Return on Equity (TTM) | -37.06% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Mind Medicine (MindMed) Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | -3.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 4.0 |
| Average | -0.10 |
|
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 0.85% |
| % Held by Institutions | 55.15% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Octagon Capital Advisors Lp | 30 Sep 2025 | 2,130,000 |
| Rosalind Advisors, Inc. | 30 Sep 2025 | 750,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 61.00 (Jones Trading, 347.21%) | Buy |
| Median | 26.50 (94.28%) | |
| Low | 20.00 (RBC Capital, 46.63%) | Buy |
| Average | 33.50 (145.60%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 12.42 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jones Trading | 23 Dec 2025 | 61.00 (347.21%) | Buy | 14.02 |
| Canaccord Genuity | 07 Nov 2025 | 25.00 (83.28%) | Buy | 11.70 |
| RBC Capital | 07 Nov 2025 | 20.00 (46.63%) | Buy | 11.70 |
| Needham | 13 Oct 2025 | 28.00 (105.28%) | Buy | 12.25 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BARROW ROBERT | - | 13.06 | -25,791 | -336,830 |
| KARLIN DANIEL | - | 13.06 | -5,600 | -73,136 |
| SULLIVAN MARK | - | 13.06 | -11,276 | -147,265 |
| Aggregate Net Quantity | -42,667 | |||
| Aggregate Net Value ($) | -557,231 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 13.06 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SULLIVAN MARK | Officer | 26 Dec 2025 | Automatic sell (-) | 11,276 | 13.06 | 147,265 |
| BARROW ROBERT | Officer | 26 Dec 2025 | Automatic sell (-) | 25,791 | 13.06 | 336,830 |
| KARLIN DANIEL | Officer | 26 Dec 2025 | Automatic sell (-) | 5,600 | 13.06 | 73,136 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |